サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1655329

リキッドバイオプシーの世界市場

Liquid Biopsy

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
リキッドバイオプシーの世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

リキッドバイオプシーの世界市場は2030年までに171億米ドルに達する見込み

2024年に63億米ドルと推定されるリキッドバイオプシーの世界市場は、2030年には171億米ドルに達し、分析期間2024-2030年のCAGRは17.9%で成長すると予測されます。リキッドバイオプシーアッセイキットは、本レポートで分析したセグメントの1つであり、CAGRは18.0％を記録し、分析期間終了時には128億米ドルに達すると予測されています。リキッドバイオプシーInstruments分野の成長率は、分析期間中CAGR 16.6％と推定されます。

米国市場は18億米ドル、中国はCAGR 17.2％で成長予測

米国のリキッドバイオプシー市場は、2024年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに26億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは17.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ15.6%と15.3%と予測されています。欧州では、ドイツがCAGR約13.1%で成長すると予測されています。

世界のリキッドバイオプシー市場- 主要動向と促進要因のまとめ

リキッドバイオプシーががんの診断と治療に革命をもたらす理由とは？

リキッドバイオプシーは、非侵襲的で正確、かつリアルタイムにがんを検出・モニタリングする方法を提供することで、がんの診断・治療分野に革命をもたらしています。サンプルを採取するために外科的処置を必要とする従来の組織生検とは異なり、リキッドバイオプシーは血液サンプルを分析し、循環腫瘍細胞（CTC）、無細胞DNA（cfDNA）、またはがんに関連するその他のバイオマーカーを検出します。このアプローチにより、がんの早期発見、病勢進行のモニタリング、治療効果の評価が可能となり、すべて患者への不快感を最小限に抑えることができます。リキッドバイオプシーが腫瘍の遺伝子構成に関する包括的な知見を提供できるようになったことで、個別化医療に変革がもたらされ、腫瘍医は個々の患者のニーズに合わせた治療をより効果的に行えるようになった。より低侵襲でより正確な診断ツールへの需要が高まるにつれ、リキッドバイオプシーは腫瘍学において価値あるツールとして急速に受け入れられています。

技術の進歩はリキッドバイオプシー市場をどのように牽引していますか？

技術の進歩は、リキッドバイオプシーの成長と採用を促進する上で重要な役割を果たしており、リキッドバイオプシーをより正確で、利用しやすく、有益なものにしています。次世代シーケンサー（NGS）やデジタルPCR（ポリメラーゼ連鎖反応）技術の革新は、リキッドバイオプシーの感度と特異性を高め、血液中の微量のがん関連バイオマーカーの検出を可能にしています。これらの進歩により、より広範な遺伝子変異の同定が可能となり、腫瘍の生物学的性質や治療反応についてより深い洞察が得られるようになっています。さらに、高度なバイオインフォマティクス・ツールの開発により、リキッドバイオプシーデータの解析と解釈が改善され、より正確で個別化された治療方針の決定が容易になっています。リキッドバイオプシーアッセイの継続的な改良は、臓器移植の拒絶反応のモニタリング、感染症の検出、出生前の遺伝的状態の評価など、腫瘍学以外にも応用の可能性を広げています。このような技術革新により、リキッドバイオプシーは精密医療においてより強力で汎用性の高いツールとなりつつあります。

どのような市場動向がリキッドバイオプシーの需要を形成していますか？

いくつかの重要な市場動向がリキッドバイオプシーの需要を形成しています。その中には、個別化医療の重視の高まり、非侵襲的診断ツールの採用の拡大、腫瘍学以外のリキッドバイオプシーアプリケーションの拡大が含まれます。個別化医療が牽引し続ける中、標的治療の指針となる詳細な遺伝子情報を提供できる診断ツールへのニーズが高まっています。リキッドバイオプシーは、腫瘍遺伝学に関するリアルタイムな洞察を提供できるため、このアプローチにおいて貴重な資産となります。非侵襲的診断の動向もリキッドバイオプシーの需要を後押ししています。患者やヘルスケアプロバイダーは、従来の組織生検に代わる、より低侵襲で快適な方法を求めているからです。さらに、リキッドバイオプシーは、移植モニタリングや感染症検出など、他の医療分野でも使用される可能性があり、市場機会を拡大しています。臨床試験や医薬品開発におけるリキッドバイオプシーの使用の増加は、治療反応や病気の進行をリアルタイムでモニタリングするための貴重なツールを提供するため、さらにその成長に寄与しています。

リキッドバイオプシー市場の成長の原動力は？

リキッドバイオプシー市場の成長は、いくつかの要因によってもたらされます。リキッドバイオプシーは従来の生検に代わる、より患者に優しい診断法を提供するため、世界のがんの発生率の上昇と、より低侵襲な診断法に対する需要の高まりが大きな推進力となっています。ゲノムと分子診断の技術的進歩はリキッドバイオプシーの精度と有用性を高め、臨床医と患者の双方にとってより魅力的な選択肢となっています。個別化医療の導入が進み、がんの進行や治療効果をリアルタイムでモニタリングする必要性が高まっていることも、市場の拡大に寄与しています。さらに、移植モニタリングや出生前検査など、腫瘍学以外の分野への応用が広がっていることも、新たな成長機会を生み出しています。リキッドバイオプシーを利用した臨床試験や研究開発の増加が市場開拓をさらに後押ししており、こうした取り組みがこの革新的技術の潜在的用途を検証し、拡大し続けています。

セグメント

提供（アッセイキット、機器、サービス）;技術（多遺伝子並列解析、単一遺伝子解析）;用途（がん、非がん）;最終用途（リファレンスラボ、病院・医師研究室、学術・研究センター、その他の最終用途）

調査対象企業の例（全42社）

  • Apostle Inc
  • Biocept, Inc.
  • BioChain Institute, Inc.
  • Biolidics Ltd.
  • CatchGene
  • Elphogene
  • F. Hoffmann-La Roche AG
  • Gencurix, Inc.
  • Genomill Health
  • Guardant Health, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP13050

Global Liquid Biopsy Market to Reach US$17.1 Billion by 2030

The global market for Liquid Biopsy estimated at US$6.3 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. Liquid Biopsy Assay Kits, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$12.8 Billion by the end of the analysis period. Growth in the Liquid Biopsy Instruments segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 17.2% CAGR

The Liquid Biopsy market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 17.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.1% CAGR.

Global Liquid Biopsy Market - Key Trends & Drivers Summarized

Why Is Liquid Biopsy Revolutionizing Cancer Diagnosis and Treatment?

Liquid biopsy is revolutionizing the field of cancer diagnosis and treatment by offering a non-invasive, accurate, and real-time method to detect and monitor cancer. Unlike traditional tissue biopsies, which require surgical procedures to obtain samples, liquid biopsies involve analyzing a blood sample to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), or other biomarkers associated with cancer. This approach allows for the early detection of cancer, monitoring of disease progression, and assessment of treatment efficacy, all with minimal discomfort to the patient. The ability of liquid biopsies to provide comprehensive insights into the genetic makeup of tumors is transforming personalized medicine, enabling oncologists to tailor treatments to individual patients' needs more effectively. As the demand for less invasive, more accurate diagnostic tools grows, liquid biopsy is rapidly gaining acceptance as a valuable tool in oncology.

How Are Technological Advancements Driving the Liquid Biopsy Market?

Technological advancements are playing a crucial role in driving the growth and adoption of liquid biopsy, making it more accurate, accessible, and informative. Innovations in next-generation sequencing (NGS) and digital PCR (Polymerase Chain Reaction) technologies are enhancing the sensitivity and specificity of liquid biopsies, allowing for the detection of minute amounts of cancer-related biomarkers in the blood. These advancements are enabling the identification of a broader range of genetic mutations, providing deeper insights into tumor biology and treatment response. Additionally, the development of advanced bioinformatics tools is improving the analysis and interpretation of liquid biopsy data, facilitating more precise and personalized treatment decisions. The ongoing refinement of liquid biopsy assays is also expanding their application beyond oncology, with potential uses in monitoring organ transplant rejection, detecting infectious diseases, and assessing prenatal genetic conditions. These technological innovations are making liquid biopsy a more powerful and versatile tool in precision medicine.

What Market Trends Are Shaping the Demand for Liquid Biopsy?

Several key market trends are shaping the demand for liquid biopsy, including the increasing emphasis on personalized medicine, the growing adoption of non-invasive diagnostic tools, and the expansion of liquid biopsy applications beyond oncology. As personalized medicine continues to gain traction, there is a growing need for diagnostic tools that can provide detailed genetic information to guide targeted therapies. Liquid biopsy's ability to offer real-time insights into tumor genetics makes it a valuable asset in this approach. The trend towards non-invasive diagnostics is also driving demand for liquid biopsy, as patients and healthcare providers seek less invasive, more comfortable alternatives to traditional tissue biopsies. Additionally, the potential for liquid biopsy to be used in other areas of medicine, such as transplant monitoring and infectious disease detection, is expanding its market opportunities. The increasing use of liquid biopsy in clinical trials and drug development is further contributing to its growth, as it provides a valuable tool for monitoring treatment response and disease progression in real-time.

What Is Driving the Growth in the Liquid Biopsy Market?

The growth in the liquid biopsy market is driven by several factors. The rising incidence of cancer worldwide and the growing demand for less invasive diagnostic methods are major drivers, as liquid biopsy offers a more patient-friendly alternative to traditional biopsies. Technological advancements in genomics and molecular diagnostics are enhancing the accuracy and utility of liquid biopsy, making it a more attractive option for both clinicians and patients. The increasing adoption of personalized medicine and the need for real-time monitoring of cancer progression and treatment response are also contributing to the market's expansion. Additionally, the broadening of liquid biopsy applications beyond oncology, such as in transplant monitoring and prenatal testing, is creating new opportunities for growth. The growing number of clinical trials and research studies utilizing liquid biopsy is further supporting market development, as these efforts continue to validate and expand the potential uses of this innovative technology.

SCOPE OF STUDY:

The report analyzes the Liquid Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Assay Kits, Instruments, Services); Technology (Multi Gene Parallel Analysis, Single Gene Analysis); Application (Cancer, Non-Cancer); End-Use (Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Apostle Inc
  • Biocept, Inc.
  • BioChain Institute, Inc.
  • Biolidics Ltd.
  • CatchGene
  • Elphogene
  • F. Hoffmann-La Roche AG
  • Gencurix, Inc.
  • Genomill Health
  • Guardant Health, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Liquid Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Clinical Applications Propel Growth in the Liquid Biopsy Market
    • Advancements in Circulating Tumor DNA (ctDNA) Technologies Drive Diagnostic Innovations
    • Integration of Liquid Biopsy with Precision Oncology Enhances Treatment Personalization
    • Rising Prevalence of Cancer Worldwide Boosts Demand for Non-Invasive Diagnostic Methods
    • Technological Breakthroughs in Single-Cell Analysis Expand Capabilities of Liquid Biopsy
    • FDA Approvals Accelerate Adoption of Liquid Biopsy Tests in Clinical Settings
    • Collaborations between Biotech Firms and Academic Institutions Fuel Research and Development
    • Growing Investment in Personalized Medicine Spurs Development of Targeted Therapies Using Liquid Biopsy
    • Market Challenges Posed by Sensitivity and Specificity Concerns in Early Cancer Detection
    • Impact of Artificial Intelligence on Enhancing Accuracy and Speed of Liquid Biopsy Analysis
    • Insurance Coverage and Reimbursement Policies Shape the Liquid Biopsy Landscape
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Assay Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Multi Gene Parallel Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Multi Gene Parallel Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Single Gene Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Non-Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Non-Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Physician Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Hospitals & Physician Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Academic & Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Academic & Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Liquid Biopsy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 94: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of World 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION